BioNexus Gene Lab Corp(BGLC)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $13.4M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
BGLC Stock Analysis & AI Quality Score
AI stock analysis and institutional research for BioNexus Gene Lab Corp (BGLC), a Healthcare sector company. BGLC is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $13.4m in revenue. Based on the latest XBRL financial filings (Q1 2026), BioNexus Gene Lab Corp reports quarterly revenue of $22.8K, net income of $-543.6K, free cash flow of $-148.0K. BGLC trades on the Nasdaq exchange and files with the SEC under CIK 1737523. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BGLC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BioNexus Gene Lab Corp directly from SEC EDGAR.
Revenue
Q1 2026
$22.8K
Net Income
Q1 2026
$-543.6K
Free Cash Flow
Q1 2026
$-148.0K
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
-2.7% YoYNet Income
+39.2% YoYOperating Income
+39.3% YoYEPS (Diluted)
+45.8% YoYTotal Assets
-8.5% YoYOp. Cash Flow
-14.9% YoY| Metric | FY 2024 | FY 2023 | FY 2021 | FY 2019 | FY 2017 |
|---|---|---|---|---|---|
| Revenue | $9.5M -2.7% | $9.8M -26.9% | $13.4M +10425.4% | $127.0K | — |
| Net Income | $-1.6M +39.2% | $-2.6M -449.8% | $751.6K +404.9% | $-246.5K | — |
| Operating Income | $-1.6M +39.3% | $-2.6M -345.6% | $1.1M +483.0% | $-275.7K | — |
| EPS (Diluted) | $-0.09 +45.8% | $-0.17 | — | — | — |
| Total Assets | $10.4M -8.5% | $11.4M +19.1% | $9.6M +677.6% | $1.2M | — |
| Operating Cash Flow | $-2.1M -14.9% | $-1.8M -19991.0% | $9.2K +104.2% | $-217.3K | — |
AI Insight: BGLC Financial Trends
BioNexus is in survival mode: revenue has collapsed to zero in recent quarters while burning ~$1M per quarter in operating losses.
• Revenue collapsed from $3M in Q3 2024 to $0M in Q4 2025 and Q1 2026, a complete loss of revenue generation.
• Operating income negative every quarter since Q2 2024; no path to profitability evident in last 9 months of data.
• Operating cash flow turned positive $1M in Q4 2025 but reverted to breakeven in Q1 2026; sustainability unclear.
⚠ Equity declined from $10M (Q2 2024) to $8M (Q1 2026); cash burn at $1M/quarter will exhaust reserves in ~8 quarters.
⚠ Zero revenue for two consecutive quarters signals either product failure, operational shutdown, or accounting issue requiring urgent clarification.
AI Insight: BGLC Ratio Trends
BioNexus collapsed from profitability in Q2 2024 to sustained losses across all metrics, with TTM operating margin at −54.4% and ROIC at −35.7%.
• Operating margin swung from +13.1% in Q2 2024 to −54.4% TTM; profitability eroded sharply starting Q3 2024.
• ROE deteriorated from +8.3% in Q2 2024 to −26.9% in Q1 2026; consistent negative returns on equity for 9 consecutive quarters.
• Q1 2026 shows modest improvement in ROE/ROA/ROIC vs. Q4 2025 (−26.9% vs. −48.1%), but remains deeply negative.
⚠ No operating or net profit margin data for Q4 2025 and Q1 2026; opaque recent quarter suggests potential restructuring or reporting delays.
⚠ ROIC has been negative for 9 consecutive quarters; capital destruction signal with no clear path to profitability visible.
Get alerted when BGLC's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for BioNexus Gene Lab Corp including:
Top Institutional Holders of BGLC
UBS Group AG
$495.00231 shWELLS FARGO & COMPANY/MN
$2.001 sh
| Fund | Value | Shares |
|---|---|---|
| UBS Group AG | $495.00 | 231 |
| WELLS FARGO & COMPANY/MN | $2.00 | 1 |
More Healthcare Companies
View all Healthcare →Put BGLC on your watchlist
Track score changes the day BioNexus Gene Lab Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is BGLC a good stock to buy?
13F Pro's AI-powered analysis of BioNexus Gene Lab Corp (BGLC) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BGLC are available on the BGLC stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own BGLC?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BGLC. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of BioNexus Gene Lab Corp's investment landscape.